Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2009 2
2010 5
2011 2
2012 2
2013 4
2014 5
2015 8
2016 5
2017 6
2018 13
2019 13
2020 5
Text availability
Article attribute
Article type
Publication date

Search Results

64 results
Results by year
Filters applied: . Clear all
Page 1
BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer.
Genta S, Pirosa MC, Stathis A. Genta S, et al. Among authors: Stathis A. Curr Oncol Rep. 2019 Feb 4;21(2):13. doi: 10.1007/s11912-019-0762-x. Curr Oncol Rep. 2019. PMID: 30715616 Review.
BET Proteins as Targets for Anticancer Treatment.
Stathis A, Bertoni F. Stathis A, et al. Cancer Discov. 2018 Jan;8(1):24-36. doi: 10.1158/2159-8290.CD-17-0605. Epub 2017 Dec 20. Cancer Discov. 2018. PMID: 29263030 Free article. Review.
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma.
Spina V, Bruscaggin A, Cuccaro A, Martini M, Di Trani M, Forestieri G, Manzoni M, Condoluci A, Arribas A, Terzi-Di-Bergamo L, Locatelli SL, Cupelli E, Ceriani L, Moccia AA, Stathis A, Nassi L, Deambrogi C, Diop F, Guidetti F, Cocomazzi A, Annunziata S, Rufini V, Giordano A, Neri A, Boldorini R, Gerber B, Bertoni F, Ghielmini M, Stüssi G, Santoro A, Cavalli F, Zucca E, Larocca LM, Gaidano G, Hohaus S, Carlo-Stella C, Rossi D. Spina V, et al. Among authors: Stathis A. Blood. 2018 May 31;131(22):2413-2425. doi: 10.1182/blood-2017-11-812073. Epub 2018 Feb 15. Blood. 2018. PMID: 29449275
The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents.
Spriano F, Chung EYL, Gaudio E, Tarantelli C, Cascione L, Napoli S, Jessen K, Carrassa L, Priebe V, Sartori G, Graham G, Selvanathan SP, Cavalli A, Rinaldi A, Kwee I, Testoni M, Genini D, Ye BH, Zucca E, Stathis A, Lannutti B, Toretsky JA, Bertoni F. Spriano F, et al. Among authors: Stathis A. Clin Cancer Res. 2019 Aug 15;25(16):5167-5176. doi: 10.1158/1078-0432.CCR-18-2718. Epub 2019 Jun 10. Clin Cancer Res. 2019. PMID: 31182435
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.
Tarantelli C, Zhang L, Curti E, Gaudio E, Spriano F, Priebe V, Cascione L, Arribas AJ, Zucca E, Rossi D, Stathis A, Bertoni F. Tarantelli C, et al. Among authors: Stathis A. Haematologica. 2019 Jul;104(7):e307-e309. doi: 10.3324/haematol.2018.214759. Epub 2019 Jan 24. Haematologica. 2019. PMID: 30679329 Free PMC article. No abstract available.
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.
Tarantelli C, Gaudio E, Arribas AJ, Kwee I, Hillmann P, Rinaldi A, Cascione L, Spriano F, Bernasconi E, Guidetti F, Carrassa L, Pittau RB, Beaufils F, Ritschard R, Rageot D, Sele A, Dossena B, Rossi FM, Zucchetto A, Taborelli M, Gattei V, Rossi D, Stathis A, Stussi G, Broggini M, Wymann MP, Wicki A, Zucca E, Cmiljanovic V, Fabbro D, Bertoni F. Tarantelli C, et al. Among authors: Stathis A. Clin Cancer Res. 2018 Jan 1;24(1):120-129. doi: 10.1158/1078-0432.CCR-17-1041. Epub 2017 Oct 24. Clin Cancer Res. 2018. PMID: 29066507 Free article.
Management of the marginal zone lymphomas.
Vannata B, Stathis A, Zucca E. Vannata B, et al. Among authors: Stathis A. Cancer Treat Res. 2015;165:227-49. doi: 10.1007/978-3-319-13150-4_9. Cancer Treat Res. 2015. PMID: 25655612 Review.
Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.
Spriano F, Tarantelli C, Gaudio E, Gerlach MM, Priebe V, Cascione L, Bernasconi E, Targa A, Mascia M, Dirnhofer S, Stathis A, Zucca E, Bertoni F. Spriano F, et al. Among authors: Stathis A. Br J Haematol. 2019 Dec;187(5):595-601. doi: 10.1111/bjh.16118. Epub 2019 Jul 29. Br J Haematol. 2019. PMID: 31355927
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.
Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, Aftimos PG, Bekradda M, Rezai K, Zeng Z, Hussain A, Perez S, Siu LL, Massard C. Lewin J, et al. Among authors: Stathis A. J Clin Oncol. 2018 Oct 20;36(30):3007-3014. doi: 10.1200/JCO.2018.78.2292. Epub 2018 May 7. J Clin Oncol. 2018. PMID: 29733771 Clinical Trial.
Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma.
Ceriani L, Milan L, Martelli M, Ferreri AJM, Cascione L, Zinzani PL, Di Rocco A, Conconi A, Stathis A, Cavalli F, Bellei M, Cozens K, Porro E, Giovanella L, Johnson PW, Zucca E. Ceriani L, et al. Among authors: Stathis A. Blood. 2018 Jul 12;132(2):179-186. doi: 10.1182/blood-2018-01-826958. Epub 2018 May 2. Blood. 2018. PMID: 29720487
64 results
Jump to page
Feedback